Table 1. Characteristics of patients on once daily and two or more times daily inhaled corticosteroid use.
| Individuals on once daily ICS use (n=221) | Individuals on ≥2 times daily ICS use (n=1,081) | P-value* | |
|---|---|---|---|
| Age in years – mean ± SD | 28.2 ± 15.8 | 31.6 ± 16.0 | 0.002 |
| Female –(%) | 113 (51.1) | 656 (60.7) | 0.009 |
| Race-ethnicity –(%) | 0.120 | ||
| African American | 67 (30.3) | 406 (37.6) | |
| White | 135 (61.1) | 586 (54.2) | |
| Other/unknown | 19 (8.6) | 89 (8.2) | |
| Asthma severity –(%)† | 0.535 | ||
| Low | 78 (35.3) | 379 (35.1) | |
| Low-moderate | 98 (44.3) | 457 (42.3) | |
| Moderate-severe | 37 (17.1) | 179 (16.6) | |
| Severe | 8 (3.6) | 66 (6.1) | |
| Type of inhaled corticosteroid used –(%)‡ | 0.001 | ||
| Beclomethasone | 2 (0.9) | 16 (1.5) | |
| Budesonide | 188 (85.1) | 665 (61.5) | |
| Flunisolide | 0 (0.0) | 1 (0.1) | |
| Fluticasone | 16 (7.2) | 288 (26.6) | |
| Mometasone | 10 (4.5) | 5 (0.5) | |
| Triamcinolone | 5 (2.3) | 106 (9.8) | |
| Taking other asthma controller medication –(%)‡ | 26 (11.8) | 96 (8.9) | 0.180 |
| Type of other controller medication used –(%)‡ | |||
| Antileukotriene | 25 (11.3) | 90 (8.3) | 0.154 |
| Cromolyn sodium | 1 (0.5) | 4 (0.4) | 0.858 |
| Omalizumab | 0 (0.0) | 3 (0.3) | 0.999 |
| Theophylline | 1 (0.5) | 2 (0.2) | 0.428 |
| ICS adherence – mean ± SD | 61 ± 34 | 41 ± 30 | 0.001 |
| ICS adherence >75% – (%) | 90 (40.7) | 187 (17.3) | 0.001 |
ICS denoted inhaled corticosteroid and SD, standard deviation.
*
P-value for comparison of individuals on once daily ICS vs. two or more times daily use.
†
Baseline asthma severity based on oral corticosteroid and short-acting beta-agonist use for the year prior to the index ICS prescription.(18)
‡
At the time of the index ICS prescription.